<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochemistry</journal-id><journal-id journal-id-type="iso-abbrev">Biochemistry</journal-id><journal-id journal-id-type="publisher-id">bi</journal-id><journal-id journal-id-type="coden">bichaw</journal-id><journal-title-group><journal-title>Biochemistry</journal-title></journal-title-group><issn pub-type="ppub">0006-2960</issn><issn pub-type="epub">1520-4995</issn><publisher><publisher-name>American
Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4230324</article-id><article-id pub-id-type="doi">10.1021/bi501121e</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>BlmB and TlmB Provide Resistance to the Bleomycin
Family of Antitumor Antibiotics by <italic>N</italic>-Acetylating
Metal-Free Bleomycin, Tallysomycin,
Phleomycin, and Zorbamycin</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Coughlin</surname><given-names>Jane M.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Rudolf</surname><given-names>Jeffrey
D.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Wendt-Pienkowski</surname><given-names>Evelyn</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Wang</surname><given-names>Liyan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Unsin</surname><given-names>Claudia</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Galm</surname><given-names>Ute</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Yang</surname><given-names>Dong</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Tao</surname><given-names>Meifeng</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath9"><name><surname>Shen</surname><given-names>Ben</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Division
of Pharmaceutical Sciences, <institution>University of
Wisconsin&#x02014;Madison</institution>, Madison, Wisconsin 53705, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Chemistry, <institution>The Scripps Research Institute</institution>, Jupiter, Florida 33458, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Molecular Therapeutics, <institution>The Scripps Research
Institute</institution>, Jupiter, Florida 33458, <country>United
States</country></aff><aff id="aff4"><label>&#x02225;</label>Natural
Products Library Initiative, <institution>The Scripps
Research Institute</institution>, Jupiter, Florida 33458, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>shenb@scripps.edu</email>. Telephone: <phone>(561) 228-2456</phone>. Fax: <fax>(561) 228-2472</fax>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>09</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="ppub"><day>11</day><month>11</month><year>2014</year></pub-date><volume>53</volume><issue>44</issue><fpage>6901</fpage><lpage>6909</lpage><history><date date-type="received"><day>05</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American Chemical
Society</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p>This is an open access article published under an ACS AuthorChoice <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-01121e_0004" id="ab-tgr1"/></p><p>The bleomycin (BLM) family of glycopeptide-derived
antitumor antibiotics
consists of BLMs, tallysomycins (TLMs), phleomycins (PLMs), and zorbamycin
(ZBM). The self-resistant elements BlmB and TlmB, discovered from
the BLM- and TLM-producing organisms <italic>Streptomyces verticillus</italic> ATCC15003 and <italic>Streptoalloteichus hindustanus</italic> E465-94
ATCC31158, respectively, are <italic>N</italic>-acetyltransferases
that provide resistance to the producers by disrupting the metal-binding
domain of the antibiotics required for activity. Although each member
of the BLM family of antibiotics possesses a conserved metal-binding
domain, the structural differences between each member, namely, the
bithiazole moiety and C-terminal amine of BLMs, have been suggested
to instill substrate specificity within BlmB. Here we report that
BlmB and TlmB readily accept and acetylate BLMs, TLMs, PLMs, and ZBM <italic>in vitro</italic> but only in the metal-free forms. Kinetic analysis
of BlmB and TlmB reveals there is no strong preference or rate enhancement
for specific substrates, indicating that the structural differences
between each member of the BLM family play a negligible role in substrate
recognition, binding, or catalysis. Intriguingly, the <italic>zbm</italic> gene cluster from <italic>Streptomyces flavoviridis</italic> ATCC21892
does not contain an <italic>N</italic>-acetyltransferase, yet ZBM
is readily acetylated by BlmB and TlmB. We subsequently established
that <italic>S. flavoviridis</italic> lacks the homologue of BlmB
and TlmB, and ZbmA, the ZBM-binding protein, alone is sufficient to
provide ZBM resistance. We further confirmed that BlmB can indeed
confer resistance to ZBM <italic>in vivo</italic> in <italic>S. flavoviridis</italic>, introduction of which into wild-type <italic>S. flavoviridis</italic> further increases the level of resistance.</p></abstract><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>bi501121e</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>bi-2014-01121e</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">Bleomycins
(BLMs), glycopeptide-derived
antibiotics produced by <italic>Streptomyces verticillus</italic>,
are clinically relevant natural products used in chemotherapy treatments
against lymphomas, squamous cell carcinomas, and testicular cancer.<sup><xref ref-type="bibr" rid="ref1">1</xref>&#x02212;<xref ref-type="bibr" rid="ref4">4</xref></sup> BLMs cause sequence-specific oxidative cleavage of double-stranded
DNA through a metal-dependent mechanism.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> BLMs contain
four functional domains (Figure <xref rid="fig1" ref-type="fig">1</xref>): (i) the
metal-binding domain comprised of pyrimidoblamic acid and the &#x003b2;-hydroxyl
histidine, (ii) the DNA-binding domain consisting of the bithiazole
moiety and C-terminal amine tail in cooperation with the aminopyrimidine
ring, (iii) a linker region connecting the metal-binding and DNA-binding
domains, and (iv) the disaccharide moiety responsible for cell selectivity<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref10">10</xref></sup> and DNA cleavage activity.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> Five nitrogen
atoms within the metal-binding domain (Figure <xref rid="fig1" ref-type="fig">1</xref>) coordinate iron and oxygen in the active form of the antibiotic.
A crystal structure of BLM bound to BlmA, the BLM-binding protein
found in the native producer, revealed that the primary amine of the
&#x003b2;-aminoalanine moiety of BLM is the axial ligand to the metal
ion in the active BLM&#x02013;metal complex form.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Structures of selected members of the bleomycin (BLM) family of
antitumor antibiotics. Structural differences between the antibiotics
are highlighted with dotted blue boxes; the five nitrogen atoms that
coordinate the metal ion are shown in bold and colored red, and the
nitrogens acetylated by BlmB and TlmB are highlighted with a solid
blue box. The four members of the BLM family selected for this study
are BLM B2, TLM A, PLM D1, and ZBM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-01121e_0006" id="gr1" position="float"/></fig><p>The tallysomycins (TLMs), phleomycins (PLMs), and zorbamycin
(ZBM),
members of the BLM family of antitumor antibiotics, are structurally
related glycopeptides.<sup><xref ref-type="bibr" rid="ref13">13</xref>&#x02212;<xref ref-type="bibr" rid="ref16">16</xref></sup> There are three major structural differences among these compounds.
(i) The bithiazole moieties in the BLMs and TLMs are replaced with
thiazolinyl-thiazole moieties in the PLMs and ZBM. (ii) ZBM contains
a unique terminal amine compared with the BLMs, TLMs, and PLMs, which
share many of the same C-terminal amines. (iii) The BLMs, TLMs, and
PLMs share the same disaccharide moiety; ZBM features a unique disaccharide,
and TLM possesses an additional sugar in the linker region. The metal-binding
domain, however, is strictly conserved among all members of the family.</p><p>Antibiotic producers must contain elements within their genomes
capable of providing self-resistance to the compounds they produce.
Generally, there are four major mechanisms of resistance to antibiotics:
antibiotic modification or destruction, target modification, antibiotic
efflux, or metabolic pathway circumvention.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Antibiotic sequestration, usually stoichiometric, is a fifth possible
mechanism.<sup><xref ref-type="bibr" rid="ref18">18</xref>&#x02212;<xref ref-type="bibr" rid="ref20">20</xref></sup><italic>Streptomyces verticillus</italic> contains
at least two of these mechanisms. BlmA, the BLM-binding protein, noncovalently
binds metal-free and metal-bound BLMs, sequestering them and thereby
preventing them from becoming active and cleaving DNA.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> BlmB, an <italic>N</italic>-acetyltransferase
that has been previously termed BAT,<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> transfers
an acetyl group from acetyl-CoA to the primary amine of the &#x003b2;-aminoalanine
moiety, the axial ligand of BLMs&#x02019; metal-binding domain.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Although acetylation does not preclude metal from binding to BLMs,
acetylation inhibits the metal-chelated complex from coordinating
to and/or reducing molecular oxygen, thereby preventing the formation
of activated BLMs.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> The resistance provided by BlmB
has been used as a selectable marker in bacteria, fungi, and mammalian
cells.<sup><xref ref-type="bibr" rid="ref25">25</xref>&#x02212;<xref ref-type="bibr" rid="ref28">28</xref></sup></p><p>Comparison of the biosynthetic gene clusters of BLM from <italic>S. verticillus</italic> ATCC15003,<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> TLM
from <italic>Streptoalloteichus hindustanus</italic> E465-94 ATCC31158,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and ZBM from <italic>Streptomyces flavoviridis</italic> ATCC21892<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> reveals all three clusters
possess homologues of the BLM-binding protein (<italic>blmA</italic>, <italic>tlmA</italic>, and <italic>zbmA</italic>, respectively)
(Figure S1 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> However, only the <italic>blm</italic> and <italic>tlm</italic> gene clusters contain genes encoding an <italic>N</italic>-acetyltransferase (<italic>blmB</italic> and <italic>tlmB</italic>, respectively), with <italic>S. flavoviridis</italic> lacking a <italic>blmB</italic> or <italic>tlmB</italic> homologue within the cloned <italic>zbm</italic> cluster. A protein sequence alignment showed BlmB is
57% identical (64% similar) to TlmB. As described above, ZBM is structurally
distinct from BLMs and TLMs by the presence of a thiazolinyl-thiazole
moiety and a unique disaccharide moiety (Figure <xref rid="fig1" ref-type="fig">1</xref>). The lack of a <italic>blmB</italic>/<italic>tlmB</italic> homologue
within the <italic>zbm</italic> gene cluster led to the speculation
that (i) ZBM might be sufficiently different and is not accepted by
an <italic>N</italic>-acetyltransferase as a substrate, (ii) a <italic>blmB</italic>/<italic>tlmB</italic> homologue may reside outside
the cloned <italic>zbm</italic> gene cluster, or (iii) ZbmA alone
is sufficient to confer resistance to ZBM in <italic>S. flavoviridis</italic>.</p><p>Given the structural similarity among the BLMs, TLMs, PLMs,
and
ZBM, specifically the conserved metal-binding domain, it is easy to
imagine BlmB or TlmB would accept any member of the BLM family of
antibiotics and catalyze acetylation. Surprisingly, BlmB was reported
to be incapable of acetylating PLM or bleomycinic acid, BLM lacking
the C-terminal amine.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> Recently, the crystal structure
of BlmB was determined, suggesting that a three-aromatic amino acid
canyonlike groove is responsible for bithiazole specificity, while
an electrostatic interaction between the negatively charged Glu188
and the positively charged terminal amine is responsible for the lack
of activity with bleomycinic acid.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p><p>Here, we report the <italic>in vitro</italic> characterization
of the two known members of the BLM family of <italic>N</italic>-acetyltransferases,
BlmB and TlmB, and an <italic>in vivo</italic> investigation of the
resistance mechanisms of ZBM in <italic>S. flavoviridis</italic> SB9001,
a ZBM overproducer derived from wild-type <italic>S. flavoviridis</italic> ATCC21892.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Our findings unveiled that
(i) BlmB and TlmB acetylate all four members of the BLM family of
antitumor antibiotics at the same primary amine of the &#x003b2;-aminoalanine
moiety, (ii) BlmB and TlmB react only on the metal-free forms of the
antibiotics, consistent with the crystal structure of BlmB,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> (iii) there is no significant preference or
rate enhancement by BlmB or TlmB for any of the four members of the
BLM family, (iv) <italic>S. flavoviridis</italic> does not possess
a <italic>blmB</italic>/<italic>tlmB</italic> homologue outside the
cloned <italic>zbm</italic> gene cluster, indicating ZbmA is sufficient
to confer resistance to ZBM in <italic>S. flavoviridis</italic>, and
(v) BlmB can confer resistance to ZBM <italic>in vivo</italic> in <italic>S. flavoviridis</italic>, introduction of which into wild-type <italic>S. flavoviridis</italic> further increases ZBM resistance.</p><sec id="sec2"><title>Materials
and Methods</title><sec id="sec2.1"><title>Bacterial Strains, Plasmids, Biochemicals, and Chemicals</title><p>Strains, plasmids, and polymerase chain reaction (PCR) primers used
in this study are summarized in Tables S1&#x02013;S3, respectively,
of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>. <italic>Escherichia coli</italic> XL1 Blue MR was used for common subcloning
and plasmid preparation.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup><italic>E. coli</italic> BL21(DE3) was used for protein overproduction. Oligonucleotide primer
synthesis and DNA sequencing were performed by the University of Wisconsin&#x02014;Madison
Biotechnology Center. The Expand High Fidelity PCR System (Roche)
was used for PCR amplification. Commerical kits (Promega) were used
for gel extraction and plasmid preparation. All restriction endonucleases
and T4 DNA ligase were purchased from NEB and reactions conducted
according to the manufacturer&#x02019;s protocols. Cu(II)-ZBM and metal-free
TLM A were isolated from <italic>S. flavoviridis</italic> SB9001 and <italic>Sa. hindustanus</italic> E465-94 ATCC31154, respectively, as previously
reported.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> Cu(II)-BLM B2 (Nippon Kayaku, Tokyo, Japan),
Cu(II)-PLM D1 (Cayla, Toulouse, France), metal-free BLM B2 (VWR International),
[<italic>acetyl</italic>-1-<sup>14</sup>C]acetyl-CoA (Moravek Biochemicals),
and EcoLume scintillation cocktail (MP Biomedicals) were purchased
from commercial sources. Other common biochemicals and chemicals were
purchased from standard commercial sources and used directly.</p></sec><sec id="sec2.2"><title>Cloning
of <italic>blmB</italic> and <italic>tlmB</italic></title><p>The <italic>blmB</italic> gene from <italic>S. verticillus</italic> ATCC15003
was amplified from pBS9<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> using
the Expand High Fidelity PCR System according to the manufacturer&#x02019;s
instructions with primers blmB_for_pET and blmB_rev_pET (Table S3
of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). The resulting
PCR products were cloned into pGEM-T Easy and verified by DNA sequencing.
The <italic>blmB</italic> gene was subcloned into the <italic>Nde</italic>I and <italic>Bam</italic>HI sites of pET14b to yield pBS64. The <italic>tlmB</italic> gene from <italic>Sa. hindustanus</italic> E465-94
ATCC31158 was amplified from pBS8001<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> with
primers tlmB_for_pET and tlmB_rev_pET (Table S3 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and cloned into pET14b
as described for <italic>blmB</italic> to yield pBS8019.</p></sec><sec id="sec2.3"><title>Overproduction
and Purification of BlmB and TlmB</title><p>The
expression constructs pBS64 and pBS8019 were transformed into <italic>E. coli</italic> BL21(DE3), and the resultant recombinant strains
were grown overnight in lysogeny broth (LB) medium containing 50 &#x003bc;g
mL<sup>&#x02013;1</sup> ampicillin. A 1 mL aliquot of the overnight
culture was used to inoculate 1 L of LB containing 50 &#x003bc;g mL<sup>&#x02013;1</sup> ampicillin and incubated at 37 &#x000b0;C while being
shaken at 250 rpm until an OD<sub>600</sub> of &#x0223c;0.6 was reached.
The temperature was reduced to 18 &#x000b0;C, and isopropyl &#x003b2;-<sc>d</sc>-1-thiogalactopyranoside (IPTG) was added to a final concentration
of 100 &#x003bc;M. The cells were incubated for an additional 18 h and
harvested by centrifugation at 4000<italic>g</italic> and 4 &#x000b0;C
for 20 min. The harvested cells were resuspended in lysis buffer [100
mM Tris-HCl (pH 8.0) containing 500 mM NaCl and 2 mM &#x003b2;-mercaptoethanol]
and lysed by sonication. Cell lysates were clarified by centrifugation
at 10000<italic>g</italic> and 4 &#x000b0;C for 30 min, and the resulting
supernatants were loaded onto 1 mL of Ni-NTA agarose (Qiagen). BlmB
and TlmB were purified by nickel affinity chromatography and desalted
using PD-10 desalting columns (GE Healthcare) using storage buffer
[25 mM Tris-HCl (pH 8.0) containing 50 NaCl and 2 mM &#x003b2;-mercaptoethanol].
The proteins were assessed for purity by sodium dodecyl sulfate&#x02013;polyacrylamide
gel electrophoresis (SDS&#x02013;PAGE) (Figure S2 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>), and protein concentrations
were determined by the Bradford method.</p></sec><sec id="sec2.4"><title>Preliminary BlmB Activity
Study by High-Performance Liquid Chromatography
(HPLC) Analysis</title><p>BlmB (485 nM) was incubated in Tris-HCl buffer
(pH 7.5) containing 500 &#x003bc;M Cu(II)-BLM B2, 1 mM acetyl-CoA, and
varying concentrations of EDTA (0, 0.125, 0.25, 0.5, 1, 3, 5, and
10 mM) for 30 min at 37 &#x000b0;C. The relative percent conversion of
BLM B2 to acetylated BLM B2 was evaluated by HPLC analysis with UV
detection at 300 nm.</p></sec><sec id="sec2.5"><title>HPLC Analysis and Characterization of the
Acetylated Products</title><p><italic>N</italic>-Acetyltransferase
reactions were performed in
20 mM Tris-HCl buffer (pH 7.5) containing 250 &#x003bc;M Cu(II)-bleomycin
analogue, 500 &#x003bc;M acetyl-CoA, 25 mM EDTA, and 485 nM BlmB or
TlmB in a total volume of 60 &#x003bc;L. For metal-free TLM A, no EDTA
was added to the reaction mixture. Incubations were conducted at 37
&#x000b0;C for 5, 10, 15, 30, or 60 min. The reactions were quenched
by removing 25 &#x003bc;L, adding CuSO<sub>4</sub> to a final concentration
of 250 &#x003bc;M, and boiling the mixture for 3 min. Negative controls
were performed in parallel using boiled BlmB or TlmB. The resultant
mixtures were analyzed by HPLC on a Varian Prostar System equipped
with an Apollo C-18 column (250 mm &#x000d7; 4.6 mm, 5 &#x003bc;m) at a
flow rate of 0.7 mL min<sup>&#x02013;1</sup> and a Varian Prostar 330
PDA detector at 300 nm.</p><p>For TLM A, the reaction mixture was
separated using a linear gradient of solvent A (0.2% acetic acid in
water) and solvent B (0.2% acetic acid in methanol): 100% A for 5
min, 0 to 75% B for 25 min, and 75 to 100% B for 5 min. Acetylated
Cu(II)-TLM A was collected, pooled, and subjected to high-resolution
matrix-assisted laser desorption ionization mass spectrometry (HR-MALDI-MS)
analysis, yielding the [M]<sup>+</sup> ion at <italic>m</italic>/<italic>z</italic> 1835.693 (calculated [M]<sup>+</sup> ion for C<sub>70</sub>H<sub>112</sub>N<sub>22</sub>O<sub>28</sub>S<sub>2</sub>Cu at <italic>m</italic>/<italic>z</italic> 1835.674).</p><p>For BLM B2, the reaction
mixture was separated using 10% solvent
B in solvent A for 5 min, 10 to 50% solvent B for 15 min, and 50 to
100% solvent B for 3 min. Acetylated Cu(II)-BLM B2 was collected,
pooled, and subjected to HR-MALDI-MS analysis, affording the [M]<sup>+</sup> ion at <italic>m</italic>/<italic>z</italic> 1529.501 (calculated
[M]<sup>+</sup> ion for C<sub>57</sub>H<sub>86</sub>N<sub>20</sub>O<sub>22</sub>S<sub>2</sub>Cu at <italic>m</italic>/<italic>z</italic> 1529.496).</p><p>For ZBM, the reaction mixture was separated using
a solvent gradient
of solvent C [1% ammonium acetate in water (pH 6.5)] and methanol:
25% methanol in solvent C for 5 min, 25 to 60% methanol for 17 min,
and 60 to 100% methanol for 3 min. Acetylated Cu(II)-ZBM was collected,
pooled, and subjected to HR-MALDI-MS analysis, affording the [M]<sup>+</sup> ion at <italic>m</italic>/<italic>z</italic> 1516.500 (calculated
[M]<sup>+</sup> ion for C<sub>57</sub>H<sub>87</sub>N<sub>19</sub>O<sub>22</sub>S<sub>2</sub>Cu at <italic>m</italic>/<italic>z</italic> 1516.501).</p><p>For PLM D1, the reaction mixture was separated
using a solvent
gradient of solvent C and methanol: 20% methanol in solvent C for
5 min, 20 to 80% methanol for 17 min, and 80 to 100% methanol for
1 min. Acetylated Cu(II)-PLM D1 was collected, pooled, and subjected
to HR-MALDI-MS analysis, yielding the [M]<sup>+</sup> ion at <italic>m</italic>/<italic>z</italic> 1531.511 (calculated [M]<sup>+</sup> ion for C<sub>57</sub>H<sub>88</sub>N<sub>20</sub>O<sub>22</sub>S<sub>2</sub>Cu at <italic>m</italic>/<italic>z</italic> 1531.512).</p></sec><sec id="sec2.6"><title>BlmB Activity Study Using <sup>14</sup>C-Labeled Acetyl-CoA
as a Substrate</title><p>Alternatively, the acetyltransferase reactions
were performed in 20 mM Tris-HCl buffer (pH 7.5) containing the selected
member of the BLM family of antibiotics at 50 &#x003bc;M [i.e., metal-free
BLM B2, Cu(II)-BLM B2, or Cu(II)-PLM D1], 500 &#x003bc;M [<italic>acetyl</italic>-1-<sup>14</sup>C]acetyl-CoA (6.7 &#x003bc;Ci &#x003bc;mol<sup>&#x02013;1</sup>), and 1.45 &#x003bc;M BlmB in a total volume of 150 &#x003bc;L. The
reactions were performed in the absence or presence of 5 mM EDTA.
Incubations were conducted at 30 &#x000b0;C, and 25 &#x003bc;L portions
were removed and spotted on Whatman P81 paper after 20 or 40 min.
The filter papers containing the dried reaction portions were washed
with 3 &#x000d7; 300 mL of water followed by 200 mL of ethanol. After
drying, the filter papers were vortexed in EcoLume scintillation cocktail
and analyzed by liquid scintillation on a Packard Tri-Carb Liquid
Scintillation Analyzer 1900 TR.</p></sec><sec id="sec2.7"><title>Kinetic Studies of BlmB
and TlmB with Four Selected Members
of the BLM Family</title><p>For kinetic analyses of BlmB and TlmB,
the four selected members of the BLM family, all in their metal-free
forms, were used. Metal-free BLM B2 was commercially available (VWR
International); metal-free TLM A was isolated from <italic>Sa. hindustanus</italic> E465-94 ATCC31158 as previously reported,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and metal-free ZBM and PLM D1 were obtained by treating the Cu(II)-complexed
forms with a solution of 0.5 M EDTA (pH 8.0) and purifying by HPLC
as previously described.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> All kinetic
assays were performed in 10 mM Tris-HCl buffer (pH 7.5) in a total
volume of 30 &#x003bc;L and incubated at 30 &#x000b0;C, and <sup>14</sup>C-labeled acetyl-CoA was used as a substrate to facilitate quantitative
analysis. After incubation, the reaction mixtures were spotted on
Whatman P81 paper, washed, dried, and scintillation counted as described
above. Each reaction was limited to &#x0003c;15% completion. For acetyl-CoA,
the assays contained 320 nM BlmB, 1 mM metal-free BLM B2, and [<italic>acetyl</italic>-1-<sup>14</sup>C]acetyl CoA concentrations of 3,
6, 12, 24, 50, 100, and 253 &#x003bc;M and were incubated for 3 min.
For BLM B2, TLM A, ZBM, and PLM D1, the assays contained 31&#x02013;271
nM BlmB or 10&#x02013;203 nM TlmB, 500 &#x003bc;M [<italic>acetyl</italic>-1-<sup>14</sup>C]acetyl-CoA (33 &#x003bc;Ci &#x003bc;mol<sup>&#x02013;1</sup>), and each member of the BLM family at concentrations of 10&#x02013;150
&#x003bc;M and were incubated for 10 min. Rates (<italic>k</italic><sub>cat</sub>) and Michaelis constants (<italic>K</italic><sub>M</sub>) were obtained from nonlinear regression analysis by SigmaPlot12.5.</p></sec><sec id="sec2.8"><title>Construction of <italic>S. flavoviridis</italic> Recombinant
Strain SB9031 with the <italic>zbm</italic> Cluster Deleted</title><p>The 5&#x02032;-distal end of the <italic>zbm</italic> cluster was
constructed by cloning the apramycin resistance gene [<italic>aac(3)IV</italic>] into the <italic>Eco</italic>RI and <italic>Nsi</italic>I sites
of pBS9024,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> yielding pBS9073. The 3&#x02032;-distal
end was constructed by first subcloning a 7 kb <italic>Pst</italic>I/<italic>Eco</italic>RI fragment from pBS9004<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> into the same sites of pGEM-3Zf and then inserting a 5
kb <italic>Eco</italic>RV/<italic>Hin</italic>dIII fragment into the <italic>Hin</italic>dIII and <italic>Ecl</italic>136I sites of pGEM-7Zf to
yield pBS9075. The two flanking ends of the <italic>zbm</italic> cluster
were combined by cloning the inset from pBS9073 into the <italic>Xba</italic>I and <italic>Pst</italic>I sites of pBS9075, followed by removal
of <italic>aac(3)IV</italic> via <italic>Eco</italic>RI and <italic>Cla</italic>I digestion, treatment with Klenow, and religation to
afford pBS9077. The insert was then subcloned into the <italic>Xba</italic>I and <italic>Pst</italic>I sites of pSET151<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> to yield pBS9078. pBS9078 was finally transformed into <italic>E.
coli</italic> S17-1 and introduced into <italic>S. flavoviridis</italic> SB9001<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> by intergeneric conjugation
following previously described methods.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref35">35</xref></sup> Homologous
recombination by a double-crossover event between <italic>S. flavoviridis</italic> SB9001 and pBS9078 afforded the mutant strain <italic>S. flavoviridis</italic> 9031, whose genotype of a <italic>zbmA-orf38</italic> deletion from
the <italic>zbm</italic> cluster was confirmed by Southern analysis
(Figure S7 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p></sec><sec id="sec2.9"><title>Construction of <italic>S. flavoviridis</italic> Recombinant
Strains SB9032, SB9033, SB9034, and SB9035 That Express <italic>blmB</italic></title><p>The <italic>blmB</italic> gene, amplified via PCR from
pBS9<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> using primers blmB_for_whm and blmB_rev_whm
(Table S3 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>) and cloned into pGEM-T Easy, was subcloned as an <italic>Xba</italic>I/<italic>Sph</italic>I fragment into the same sites of two <italic>Streptomyces</italic> expression vectors, pWHM860<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> and pWHM1250,<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> to yield pBS65
and pBS66, respectively. While the expression of <italic>blmB</italic> in pBS65 is under the control of its putative native promoter, pBS66
differed from pBS65 by placing <italic>blmB</italic> under the control
of the strong promoter <italic>ErmE*</italic>, thereby ensuring its
expression in <italic>Streptomyces</italic>.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Introduction of plasmids pBS65 and pBS66 into <italic>S. flavoviridis</italic> SB9001 and SB9031, respectively, was accomplished by protoplast
transformation following standard procedures,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> affording recombinant <italic>S. flavoviridis</italic> strains SB9032
(i.e., SB9001/pBS65), SB9033 (i.e., SB9001/pBS66), SB9034 (i.e., SB9031/pBS65),
and SB9035 (i.e., SB9031/pBS66).</p></sec><sec id="sec2.10"><title>ZBM Resistance Determined
by a Disk Diffusion Assay</title><p>A standard disk diffusion assay
was used to determine the susceptibility
of wild-type and recombinant <italic>S. flavoviridis</italic> strains
to Cu(II)-ZBM. Briefly, quantities of Cu(II)-ZBM (0&#x02013;500 &#x003bc;g)
in methanol were applied to 7 mm paper disks (Whatman) and dried.
The disks were placed on solid TSB agar plates applied with a liquid
spore suspension containing 2 &#x000d7; 10<sup>8</sup> spores of the
recombinant <italic>S. flavoviridis</italic> strains, SB9031, SB9032,
SB9033, SB9034, and SB9035, with the ZBM overproducer <italic>S. flavoviridis</italic> SB9001<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> as a control. These plates were
incubated at 30 &#x000b0;C for &#x0223c;48 h to determine the zones of
inhibition as a measurement of ZBM resistance.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3.1"><title>Cloning, Gene
Expression, and Purification of BlmB and TlmB</title><p>The <italic>blmB</italic> gene from <italic>S. verticillus</italic> ATCC15003
and the <italic>tlmB</italic> gene from <italic>Sa. hindustanus</italic> E465-94 ATCC31158 were amplified by PCR, cloned into pET14b to afford
pBS64 and pBS8019, respectively, and transformed into <italic>E. coli</italic> BL21(DE3) for overexpression. BlmB and TlmB were overproduced as
N-terminal His<sub>6</sub>-tagged fusion proteins and purified to
homogeneity by Ni-NTA agarose affinity chromatography. The purified
proteins showed single bands upon SDS&#x02013;PAGE analysis consistent
with the predicted molecular masses of BlmB (34388.8 Da) and TlmB
(34422.2 Da) (Figure S2 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p></sec><sec id="sec3.2"><title>BlmB and TlmB Acetylate the Metal-Free Forms of BLM B2, TLM
A, PLM D1, and ZBM</title><p>As previously reported,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> BlmB is unable to catalyze the acetylation of metal-bound
BLMs. Incubation of 500 &#x003bc;M Cu(II)-BLM B2 with 1 mM acetyl-CoA
and 485 nM BlmB or TlmB showed &#x0003c;4% turnover after 30 min. The addition
of EDTA led to &#x0003e;80% turnover of BLM B2 under the same conditions
(Figure
S3 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). The
formation of acetylated BLM B2 was confirmed by HR-MALDI-MS.</p><p>An end point assay utilizing <sup>14</sup>C-labeled acetyl-CoA ([<italic>acetyl</italic>-1-<sup>14</sup>C]acetyl-CoA), BLM B2 or PLM D1, and
BlmB further confirmed the metal-free antibiotics as the preferred
forms of the substrates. Metal-free BLM B2 and Cu(II)-bound BLM B2
or PLM D1 in the presence of EDTA showed significant turnover compared
to that of the Cu(II)-bound antibiotic in the absence of EDTA (Figure
S4 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p><p>Although previous studies reported BlmB did not acetylate bleomycinic
acid or PLM,<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> our previous work on isolating
TLMs<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and ZBM<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref31">31</xref></sup> afforded us the opportunity to examine the substrate flexibility
of BlmB comparatively with each of the four members of the BLM family.
Both BlmB and TlmB were assayed using Cu(II)-BLM B2, TLM A, Cu(II)-PLM
D1, or Cu(II)-ZBM as a substrate with EDTA included in each reaction
mixture. After 30 min, the reactions were quenched by boiling, and
CuSO<sub>4</sub> was added to simplify HPLC analysis as the copper-bound
and metal-free antibiotics elute at different retention times. HPLC
analysis of each reaction mixture confirmed that both BlmB and TlmB
are capable of acetylating BLM B2, TLM A, PLM D1, and ZBM (Figure <xref rid="fig2" ref-type="fig">2</xref>). Each acetylated product was confirmed by HR-MALDI-MS.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>BlmB and
TlmB acetylate four members of the BLM family of antitumor
antibiotics, BLM B2, TLM A, PLM D1, and ZBM. HPLC analysis of <italic>in vitro</italic> enzyme reactions: (A) BLM B2 with BlmB, (B) TLM
A with BlmB, (C) PLM D1 with BlmB, (D) ZBM with BlmB, (E) BLM B2 with
TlmB, (F) TLM A with TlmB, (G) PLM D1 with TlmB, and (H) ZBM with
TlmB. Panels A and E (BLM B2), B and F (TLM A), C and G (PLM D1),
and D and H (ZBM) each show 30 min (I) and 15 min (II), 15 min (I)
and 5 min (II), 60 min (I) and 30 min (II), and 10 min (I) and 5 min
(II) reactions, respectively, and enzyme-boiled negative controls
(III). Highlighted compounds are the antibiotic substrate (&#x025cf;)
and acetylated product (*).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-01121e_0001" id="gr2" position="float"/></fig></sec><sec id="sec3.3"><title>Kinetic Characterization of BlmB and TlmB Reveals No Substantial
Preference for Any Member of the BLM Family</title><p>Michaelis&#x02013;Menten
kinetic parameters for the four selected members of the BLM family,
each in its metal-free form, are listed in Table <xref rid="tbl1" ref-type="other">1</xref>. Rates (<italic>k</italic><sub>ca<italic>t</italic></sub>) and Michaelis constants (<italic>K</italic><sub>M</sub>) were determined
from a nonlinear regression fit of initial velocities versus concentration
(Figures S5 and S6 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). For BlmB, the <italic>K</italic><sub>M</sub> for acetyl-CoA was
determined to be 19 &#x003bc;M, which corresponded well with the previously
reported value of 12 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Previous
kinetic studies with BlmB showed substrate inhibition at 12 &#x003bc;M
BLM A2 at pH &#x0003e;6.0.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The reported <italic>K</italic><sub>M</sub> value for BLM A2 (at pH 6.0) was 11 &#x003bc;M,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> correlating well with a previous <italic>K</italic><sub>M</sub> value for BLM A2 of 13 &#x003bc;M.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> In our hands, BlmB and TlmB showed no substrate inhibition
at pH 7.5 yet similar <italic>K</italic><sub>M</sub> values of 15
and 19 &#x003bc;M, respectively, for BLM B2. In fact, each member of
the BLM family had comparable <italic>K</italic><sub>M</sub> values
for both BlmB and TlmB. Rates (<italic>k</italic><sub>cat</sub>) for
each substrate also had similar values, which were comparable with
previously reported values using BLM A2,<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> with only ZBM showing a modest enhancement in rate versus those
of the other members of the BLM family.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Kinetic
Parameters for BlmB and TlmB
with Four Selected Members of the BLM Family of Antitumor Antibiotics<xref rid="t1fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="4" align="center">BlmB<hr/></th><th colspan="4" align="center">TlmB<hr/></th></tr><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">BLM&#x000a0;B2</th><th style="border:none;" align="center">TLM&#x000a0;A</th><th style="border:none;" align="center">PLM&#x000a0;D1</th><th style="border:none;" align="center">ZBM</th><th style="border:none;" align="center">BLM&#x000a0;B2</th><th style="border:none;" align="center">TLM&#x000a0;A</th><th style="border:none;" align="center">PLM&#x000a0;D1</th><th style="border:none;" align="center">ZBM</th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>k</italic><sub>cat</sub> (min<sup>&#x02013;1</sup>)</td><td style="border:none;" align="left">12&#x000a0;&#x000b1;&#x000a0;2</td><td style="border:none;" align="left">8.2&#x000a0;&#x000b1;&#x000a0;1.7</td><td style="border:none;" align="left">1.9&#x000a0;&#x000b1;&#x000a0;0.5</td><td style="border:none;" align="left">29&#x000a0;&#x000b1;&#x000a0;3</td><td style="border:none;" align="left">6.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td style="border:none;" align="left">4.4&#x000a0;&#x000b1;&#x000a0;0.6</td><td style="border:none;" align="left">2.2&#x000a0;&#x000b1;&#x000a0;0.4</td><td style="border:none;" align="left">21&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td style="border:none;" align="left"><italic>K</italic><sub>M</sub> (&#x003bc;M)</td><td style="border:none;" align="left">15&#x000a0;&#x000b1;&#x000a0;5</td><td style="border:none;" align="left">45&#x000a0;&#x000b1;&#x000a0;17</td><td style="border:none;" align="left">40&#x000a0;&#x000b1;&#x000a0;25</td><td style="border:none;" align="left">21&#x000a0;&#x000b1;&#x000a0;9</td><td style="border:none;" align="left">19&#x000a0;&#x000b1;&#x000a0;5</td><td style="border:none;" align="left">42&#x000a0;&#x000b1;&#x000a0;14</td><td style="border:none;" align="left">40&#x000a0;&#x000b1;&#x000a0;16</td><td style="border:none;" align="left">25&#x000a0;&#x000b1;&#x000a0;6</td></tr><tr><td style="border:none;" align="left"><italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>M</sub> (s<sup>&#x02013;1</sup>&#x000a0;M<sup>&#x02013;1</sup>)</td><td style="border:none;" align="left">1.3&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td style="border:none;" align="left">3.0&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup></td><td style="border:none;" align="left">7.9&#x000a0;&#x000d7;&#x000a0;10<sup>2</sup></td><td style="border:none;" align="left">2.3&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td><td style="border:none;" align="left">5.4&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup></td><td style="border:none;" align="left">1.7&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup></td><td style="border:none;" align="left">9.2&#x000a0;&#x000d7;&#x000a0;10<sup>2</sup></td><td style="border:none;" align="left">1.4&#x000a0;&#x000d7;&#x000a0;10<sup>4</sup></td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>The values are
averages of at least
two independent assays and are reported with standard errors.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.4"><title><italic>S. flavoviridis</italic> Does Not
Possess a <italic>blmB</italic>/<italic>tlmB</italic> Homologue Outside
the Cloned <italic>zbm</italic> Gene Cluster</title><p>Given the ability
of BlmB and
TlmB to efficiently acetylate ZBM <italic>in vitro</italic>, it is
surprising that the cloned <italic>zbm</italic> gene cluster does
not possess a <italic>blmB</italic>/<italic>tlmB</italic> homologue.
To determine if a <italic>blmB</italic>/<italic>tlmB</italic> homologue
resides outside the cloned <italic>zbm</italic> gene cluster, we deleted
the <italic>zbm</italic> gene cluster from <italic>S. flavoviridis</italic> SB9001, a ZBM overproducer derived from the wild-type <italic>S.
flavoviridis</italic> ATCC21892 strain,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> to afford recombinant strain <italic>S. flavoviridis</italic> SB9031;
the <italic>&#x00394;zbmA</italic>-<italic>orf38</italic> genotype of <italic>S. flavoviridis</italic> SB9031 was confirmed by Southern analysis
(Figure S7 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). <italic>S. flavoviridis</italic> SB9031 is incapable of ZBM production
and eliminates the only known form of self-resistance to ZBM, the
ZBM-binding protein ZbmA. The susceptibility of <italic>S. flavoviridis</italic> SB9031 to Cu(II)-ZBM was determined using the disk diffusion assay.
While <italic>S. flavoviridis</italic> SB9001 showed resistance up
to 20 &#x003bc;g of ZBM per disk, the <italic>S. flavoviridis</italic> SB9031 mutant was sensitive at quantities as low as 0.5&#x02013;1
&#x003bc;g of ZBM per disk, excluding the existence of other resistance
elements on the <italic>S. flavoviridis</italic> SB9031 genome (Figure <xref rid="fig3" ref-type="fig">3</xref>A).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Disk diffusion assays for Cu(II)-ZBM susceptibility of
selected <italic>S. flavoviridis</italic> recombinant strains in comparison
with the
wild-type strain. (A) SB9001 (wild-type) and SB9031 (&#x00394;<italic>zbmA-orf38</italic>) challenged with 0, 0.1, 0.5, 1, 5, 10, and 20
&#x003bc;g of Cu(II)-ZBM (clockwise from the top right filter, respectively).
(B) SB9034 (i.e., SB9031/pBS65 expressing <italic>blmB</italic> under
its putative native promoter) and SB9035 (i.e., SB9031/pBS66 expressing <italic>blmB</italic> under the <italic>ErmE</italic>* promoter) challenged
with 0, 0.1, 0.5, 1, 5, 10, and 20 &#x003bc;g of Cu(II)-ZBM (clockwise
from the top right filter, respectively).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-01121e_0002" id="gr3" position="float"/></fig></sec><sec id="sec3.5"><title>Expression of <italic>blmB</italic> Confers ZBM Resistance in <italic>S. flavoviridis</italic><italic>in Vivo</italic></title><p>To determine
if BlmB is capable of acetylating ZBM <italic>in vivo</italic>, as
demonstrated <italic>in vitro</italic>, two <italic>blmB</italic> expression
plasmids, pBS65 and pBS66, placing <italic>blmB</italic> under its
putative native promoter and the strong promoter <italic>ErmE*</italic> to ensure its expression in <italic>Streptomyces</italic>, respectively,
were constructed. Introduction of pBS65 and pBS66 into <italic>S.
flavoviridis</italic> SB9001 and SB9031, respectively, afforded recombinant
strains SB9032, SB9033, SB9034, and SB9035. These strains were assayed
for Cu(II)-ZBM susceptibility using the disk diffusion assay with
the parent <italic>S. flavoviridis</italic> SB9001 and SB9031 strains
as controls. Expression of <italic>blmB</italic> in SB9031 indeed
resulted in a significant increase in ZBM resistance. This was evident
in <italic>S. flavoviridis</italic> SB9034, which showed resistance
up to 10 &#x003bc;g of ZBM per disk, an increase of &#x0003e;10-fold versus
that of the parent mutant SB9031. <italic>S. flavoviridis</italic> SB9035 showed a complete recovery of ZBM resistance as compared
to the parent wild-type strain SB9001, presumably because of the enhanced
expression of <italic>blmB</italic> under <italic>ErmE*</italic> (Figure <xref rid="fig3" ref-type="fig">3</xref>B). Similarly, expression of <italic>blmB</italic> in <italic>S. flavoviridis</italic> SB9001 also increased the level
of ZBM resistance; this was more apparent in <italic>S. flavoviridis</italic> SB9033, where <italic>blmB</italic> expression was enhanced by <italic>ErmE</italic>*, than in SB9032 (Figure S8 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>The
BLM <italic>N</italic>-acetyltransferase (BlmB) is a resistance
element found within the <italic>blm</italic> gene cluster of <italic>S. verticillus</italic> ATCC15003 that bestows self-resistance to
BLM by acetylating the primary amine of its &#x003b2;-aminoalanine moiety,
the axial ligand of the BLM-metal ion-binding domain. As there are
many examples of bacterial self-resistance elements conferring resistance
to a family of antimicrobial agents,<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref38">38</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> it was surprising to discover BlmB was capable of
acetylating only BLM and not other members of the BLM family of antitumor
antibiotics, particularly PLM, a compound identical to BLM except
for the presence of a thiazolinyl-thiazole moiety instead of the bithiazole
moiety found in BLM.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> A crystal structure
of BlmB implied that a canyonlike groove of three aromatic side chains
is too narrow to accommodate the nonplanar thiazoline ring of PLM.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> Interestingly, the <italic>zbm</italic> gene
cluster from <italic>S. flavoviridis</italic> ATCC21892 does not contain
a <italic>blmB</italic>/<italic>tlmB</italic> homologue,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> suggesting ZBM, a thiazolinyl-thiazole-containing
analogue of BLM, would not be acetylated by a BlmB-like enzyme. In
this study, we determined whether BlmB and TlmB can acetylate BLM
B2, TLM A, PLM D1, and ZBM, four members of the BLM family, <italic>in vitro</italic> and investigated the resistance mechanisms of the
ZBM producer <italic>S. flavoviridis</italic><italic>in vivo</italic>.</p><p>Both BlmB and TlmB acetylate BLM B2, TLM A, PLM D1, and ZBM,
but
only the metal-free forms, <italic>in vitro</italic>. Although metal-free
BLM as a requirement for BlmB activity was previously stated,<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> it appeared to be anecdotal as we found no experimental
evidence in the literature. Comparisons of the BLM structures (Figure <xref rid="fig4" ref-type="fig">4</xref>A),<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> free and enzyme-bound, reveal a probable cause for the lack of acetylation
of the metal-bound forms of BLMs by BlmB and TlmB. When metal is coordinated
to the five nitrogens of BLM, as in the case of the Cu(II)-BLM complex
bound to BlmA or the Co(II)-BLM complex alone, the metal-binding domain
forms a compact conformation. Conversely, BLM in BlmB must adopt an
open conformation allowing the primary amine of BLM access to acetyl-CoA.
The tight conformation of BLM when bound to metal likely precludes
the correct binding orientation in BlmB necessary for catalysis and
prevents BlmB from pulling apart the tightly chelated nitrogen atoms
(Figure <xref rid="fig4" ref-type="fig">4</xref>A).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>(A) Conformations of free and enzyme-bound
BLM reveal its structural
flexibility: (I) free Co(II)-BLM A2 (Protein Data Bank entry 1DEY), (II) Cu(II)-BLM
A2 bound to BlmA (Protein Data Bank entry 1JIF), and (III) BLM A2 bound to BlmB (Protein
Data Bank entry 2ZW7). Enzymes are not shown. Co(II) or Cu(II) atoms are shown as gold
spheres. The five metal-coordinating nitrogens are shown as blue spheres.
For II and III, the bithiazole moieties and C-terminal amines are
cropped at the double wavy lines. The tight conformation of the metal-binding
domain in metal-bound BLM likely prevents BLM from correctly binding
to BlmB for acetylation. (B) Unified model for self-resistance within
the producers of the BLM family of antitumor antibiotics as exemplified
by the BLM producer. Activated BLM (or TLM or ZBM) is generated by
binding to a metal ion [M(II)] and molecular oxygen (O<sub>2</sub>), which is then reduced to form BLM-M(III)-OOH (black box). Resistance
in the native producer is primarily achieved through sesquestration
by BlmA (thick blue box), while antibiotic modification by BlmB (thin
green box) provides an additional mechanism of resistance. BlmB acetylates
the axial ligand of the BLM metal-binding domain, but only in the
presence of metal-free BLM. Acetylated BLM (Ac-BLM) can bind metal,
but O<sub>2</sub> binding or activation is inhibited. BlmA tightly
binds metal-bound BLM, preventing O<sub>2</sub> binding and activation.
For the sake of simplicity, the coordinated metal ion is represented
as an M. Members of the BLM family are isolated as Cu(II) complexes;
structures have been determined as Cu or Co complexes, and Fe(II)
must bind before activated BLM is generated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi-2014-01121e_0003" id="gr4" position="float"/></fig><p>The BlmB and TlmB enzymes were kinetically characterized
with four
members of the BLM family, each in metal-free forms, and surprisingly,
both the rates (<italic>k</italic><sub>cat</sub>) and Michaelis constants
(<italic>K</italic><sub>M</sub>) for each member were essentially
equivalent. Comparable Michaelis constants indicate each member, regardless
of its differences in structure, binds favorably for the reaction
to occur. Thus, the narrow bithiazole binding groove in BlmB does
not prevent the correct binding orientation necessary for acetylation
to occur in thiazolinyl-thiazole analogues. A sequence alignment of
BlmB and TlmB reveals only two of the three aromatic side chains in
the canyonlike groove are conserved (Figure S9 of the <xref rid="notes-2" ref-type="notes">Supporting Information</xref>). One could imagine a
Phe/Val substitution, as in the case of BlmB and TlmB, may provide
the necessary space to better accommodate a nonplanar thiazoline ring.
However, neither BlmB nor TlmB shows a preference for bithiazole as
in BLM B2 and TLM A or thiazolinyl-thiazole as in PLM D1 and ZBM,
suggesting the canyonlike groove plays little role in substrate recognition
and specificity.</p><p>The BLM-binding proteins have long been known
for their sequestration,
and therefore inactivation, of members of the BLM family of antitumor
antibiotics.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> The structure of BlmA, the BLM-binding protein
from <italic>S. verticillus</italic> ATCC15003, was determined with
bound BLM B2 in both the metal-free and Cu(II)-complexed forms,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> suggesting BlmA can bind either form of BLM
and thus confer resistance in either situation. Given the significant
structural similarity of both BlmA and BLM B2 in both the metal-free
and Cu(II)-complexed forms and the fact that BLMs are isolated as
Cu(II) complexes,<sup><xref ref-type="bibr" rid="ref15">15</xref>,<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup> BlmA likely preferentially binds metal-bound BLMs <italic>in vivo</italic> (Figure <xref rid="fig4" ref-type="fig">4</xref>B). As experimentally determined
in this study, BlmB acetylates only the metal-free form of BLMs. As
members of the metal-free forms of the BLM family are incapable of
causing DNA damage,<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref43">43</xref></sup> BlmB and TlmB appear to inactivate
an unharmful form of an antibiotic. Although counterintuitive, covalent
modification of an inactive antibiotic by BlmB or TlmB immediately
after its biosynthesis may provide a preemptive and complementary
mechanism of resistance from self-imposed oxidative damage (Figure <xref rid="fig4" ref-type="fig">4</xref>B) and/or a more stable, yet potentially reversible,
inactivation. It is not clear, however, when and at what level the <italic>blmB/tlmB</italic> gene is expressed during biosynthesis. We suspect
BlmB or TlmB acts on only the final biosynthetic product, a model
that is consistent with our <italic>in vitro</italic> data, previously
reported studies,<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> and the numerous contacts
BlmB makes with the four functional domains of BLM.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> This hypothesis would rule out BlmB acetylating a biosynthetic
intermediate or precursor.</p><p>We previously reported that the cloned <italic>zbm</italic> cluster
from <italic>S. flavoviridis</italic> ATCC21892 lacks the <italic>blmB/tlmB</italic> homologue, implying BlmA or TlmA performs the
essential role in BLM resistance.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> We
now establish that <italic>S. flavoviridis</italic> does not possess
a <italic>blmB</italic>/<italic>tlmB</italic> homologue in its genome. <italic>S. flavoviridis</italic> therefore appears to forego the BlmB resistance
mechanism of antibiotic modification, and ZbmA alone must be sufficient
to provide ZBM resistance. With these findings and the fact that Cu(II)-BLM
complexes are isolated, we now propose that the mechanism of sequestration
by BlmA, TlmA, and ZbmA is the primary mechanism of resistance. BlmB
and TlmB may then be considered as a secondary mechanism of resistance.
Indeed, we show that BlmB can confer resistance to ZBM <italic>in
vivo</italic> in the ZBM-sensitive <italic>S. flavoviridis</italic> SB9031 strain and that introduction of BlmB into wild-type <italic>S. flavoviridis</italic> SB9001 further increases ZBM resistance
as exemplified by the SB9033 strain. The reacquisition of ZBM resistance
in sensitive strain <italic>S. flavoviridis</italic> SB9031 by expression
of <italic>blmB</italic> confirms that ZBM can be inactivated by a
BlmB homologue <italic>in vivo</italic> and proves BlmB can confer
resistance as the sole resistance element.</p><p>This study highlights
the biochemical functionality and antibiotic
resistance mechanism of the BLM family of antitumor antibiotics by
the BLM <italic>N</italic>-acetyltransferases. Comparison among the <italic>blm</italic>, <italic>tlm</italic>, and <italic>zbm</italic> gene
clusters exposes the evolutionary relationship between the BlmB and
TlmB <italic>N</italic>-acetyltransferases and the BlmA-, TlmA-, and
ZbmA-binding proteins as mechanisms of resistance to the BLM family
of drugs. On the basis of this study, we now propose a unified model
for self-resistance within the producers of BLM, TLM, and ZBM, with
BlmA, TlmA, and ZbmA providing the primary mechanism of resistance
and BlmB and TlmB as a secondary additional mechanism of resistance.</p></sec></body><back><notes id="notes-2" notes-type="si"><title>Supporting Information Available</title><p>Strains,
plasmids, and primers
used in this study (Tables S1&#x02013;S3), organization of the biosynthetic
gene clusters of BLM, TLM, and ZBM (Figure S1), SDS&#x02013;PAGE analysis
of BlmB and TlmB (Figure S2), acetylation of Cu(II)-BLM by BlmB in
the presence of EDTA (Figure S3), BlmB end point assay utilizing radiolabeled
acetyl-CoA (Figure S4), Michaelis&#x02013;Menten curves (Figures S5
and S6), Southern analysis of the &#x00394;<italic>zbmA-orf38</italic> mutant <italic>S. flavoviridis</italic> SB9031 (Figure S7), disk
diffusion assays for Cu(II)-ZBM susceptibility in <italic>S. flavoviridis</italic> SB9001, SB9032, and SB9033 (Figure S8), and a sequence alignment
of BlmB and TlmB (Figure S9). This material is available free of charge
via the Internet at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>.</p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bi501121e_si_001.pdf"><caption><p>bi501121e_si_001.pdf</p></caption></media></supplementary-material></sec><notes id="notes-1"><title>Author Contributions</title><p>J.C. and
J.D.R. contributed equally to this work.</p></notes><notes id="notes-77" notes-type="funding-statement"><p>This work is
supported in part by National Institutes of Health Grant CA094426
and the Natural Products Library Initiative at The Scripps Research
Institute.</p></notes><notes id="notes-3" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bayer</surname><given-names>R. A.</given-names></name>; <name><surname>Gaynor</surname><given-names>E. R.</given-names></name>; <name><surname>Fisher</surname><given-names>R. I.</given-names></name> (<year>1992</year>) <article-title>Bleomycin in non-Hodgkin&#x02019;s
lymphoma</article-title>. <source>Semin. Oncol.</source>
<volume>19</volume>, <fpage>46</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">1384144</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Einhorn</surname><given-names>L. H.</given-names></name> (<year>2002</year>) <article-title>Curing
metastatic testicular cancer</article-title>. <source>Proc. Natl. Acad.
Sci. U.S.A.</source>
<volume>99</volume>, <fpage>4592</fpage>&#x02013;<lpage>4595</lpage>.<pub-id pub-id-type="pmid">11904381</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Stubbe</surname><given-names>J.</given-names></name> (<year>2005</year>) <article-title>Bleomycins: Towards
better therapeutics</article-title>. <source>Nat. Rev. Cancer</source>
<volume>5</volume>, <fpage>102</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">15685195</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Hager</surname><given-names>M. H.</given-names></name>; <name><surname>Van Lanen</surname><given-names>S. G.</given-names></name>; <name><surname>Ju</surname><given-names>J.</given-names></name>; <name><surname>Thorson</surname><given-names>J. S.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2005</year>) <article-title>Antitumor antibiotics: Bleomycin,
enediynes, and mitomycin</article-title>. <source>Chem. Rev.</source>
<volume>105</volume>, <fpage>739</fpage>&#x02013;<lpage>758</lpage>.<pub-id pub-id-type="pmid">15700963</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Burger</surname><given-names>R. M.</given-names></name>; <name><surname>Peisach</surname><given-names>J.</given-names></name>; <name><surname>Horwitz</surname><given-names>S. B.</given-names></name> (<year>1981</year>) <article-title>Activated
bleomycin. A transient
complex of drug, iron, and oxygen that degrades DNA</article-title>. <source>J. Biol. Chem.</source>
<volume>256</volume>, <fpage>11636</fpage>&#x02013;<lpage>11644</lpage>.<pub-id pub-id-type="pmid">6170635</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Stubbe</surname><given-names>J.</given-names></name>; <name><surname>Kozarich</surname><given-names>J. W.</given-names></name> (<year>1987</year>) <article-title>Mechanisms of bleomycin-induced DNA degradation</article-title>. <source>Chem. Rev.</source>
<volume>87</volume>, <fpage>1107</fpage>&#x02013;<lpage>1136</lpage>.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Schmaltz</surname><given-names>R. M.</given-names></name>; <name><surname>Bozeman</surname><given-names>T. C.</given-names></name>; <name><surname>Paul</surname><given-names>R.</given-names></name>; <name><surname>Rishel</surname><given-names>M. J.</given-names></name>; <name><surname>Tsosie</surname><given-names>K. S.</given-names></name>; <name><surname>Hecht</surname><given-names>S. M.</given-names></name> (<year>2013</year>) <article-title>Selective tumor cell targeting by
the disaccharide moiety of bleomycin</article-title>. <source>J. Am.
Chem. Soc.</source>
<volume>135</volume>, <fpage>2883</fpage>&#x02013;<lpage>2886</lpage>.<pub-id pub-id-type="pmid">23379863</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Chapuis</surname><given-names>J.-C.</given-names></name>; <name><surname>Schmaltz</surname><given-names>R. M.</given-names></name>; <name><surname>Tsosie</surname><given-names>K. S.</given-names></name>; <name><surname>Belohlavek</surname><given-names>M.</given-names></name>; <name><surname>Hecht</surname><given-names>S. M.</given-names></name> (<year>2009</year>) <article-title>Carbohydrate dependent targeting
of cancer cells by
bleomycin-microbubble conjugates</article-title>. <source>J. Am. Chem.
Soc.</source>
<volume>131</volume>, <fpage>2438</fpage>&#x02013;<lpage>2439</lpage>.<pub-id pub-id-type="pmid">19187019</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Boger</surname><given-names>D. L.</given-names></name>; <name><surname>Cai</surname><given-names>H.</given-names></name> (<year>1999</year>) <article-title>Review of bleomycin:
Synthetic and mechanistic studies</article-title>. <source>Angew. Chem.,
Int. Ed.</source>
<volume>38</volume>, <fpage>448</fpage>&#x02013;<lpage>476</lpage>.</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Hecht</surname><given-names>S. M.</given-names></name> (<year>2000</year>) <article-title>Bleomycin:
New perspectives on the mechanism of action</article-title>. <source>J. Nat. Prod.</source>
<volume>63</volume>, <fpage>158</fpage>&#x02013;<lpage>168</lpage>.<pub-id pub-id-type="pmid">10650103</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Huang</surname><given-names>S.-X.</given-names></name>; <name><surname>Feng</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name>; <name><surname>Yang</surname><given-names>D.</given-names></name>; <name><surname>Tao</surname><given-names>M.</given-names></name>; <name><surname>Coughlin</surname><given-names>J. M.</given-names></name>; <name><surname>Duan</surname><given-names>Y.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2012</year>) <article-title>A designer bleomycin with significantly improved DNA cleavage activity</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>134</volume>, <fpage>13501</fpage>&#x02013;<lpage>13509</lpage>.<pub-id pub-id-type="pmid">22831455</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Sugiyama</surname><given-names>M.</given-names></name>; <name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Hayashida</surname><given-names>M.</given-names></name>; <name><surname>Maruyama</surname><given-names>M.</given-names></name>; <name><surname>Matoba</surname><given-names>Y.</given-names></name> (<year>2002</year>) <article-title>The 1.6-&#x000c5;
crystal structure of the copper(II)-bound bleomycin complexed with
the bleomycin-binding protein from bleomycin-producing <italic>Streptomyces
verticillus</italic></article-title>. <source>J. Biol. Chem.</source>
<volume>277</volume>, <fpage>2311</fpage>&#x02013;<lpage>2320</lpage>.<pub-id pub-id-type="pmid">11706014</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>S.-X.</given-names></name>; <name><surname>Unsin</surname><given-names>C.</given-names></name>; <name><surname>Tao</surname><given-names>M.</given-names></name>; <name><surname>Coughlin</surname><given-names>J. M.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2011</year>) <article-title>Comparative analysis of the biosynthetic
gene clusters and pathways for three structurally related antitumor
antibiotics: Bleomycin, tallysomycin, and zorbamycin</article-title>. <source>J. Nat. Prod.</source>
<volume>74</volume>, <fpage>526</fpage>&#x02013;<lpage>536</lpage>.<pub-id pub-id-type="pmid">21210656</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Konishi</surname><given-names>M.</given-names></name>; <name><surname>Saito</surname><given-names>K.</given-names></name>; <name><surname>Numata</surname><given-names>K.</given-names></name>; <name><surname>Tsuno</surname><given-names>T.</given-names></name>; <name><surname>Asama</surname><given-names>K.</given-names></name>; <name><surname>Tsukiura</surname><given-names>H.</given-names></name>; <name><surname>Naito</surname><given-names>T.</given-names></name>; <name><surname>Kawaguchi</surname><given-names>H.</given-names></name> (<year>1977</year>) <article-title>Tallysomycin,
a new antitumor antibiotic complex related to bleomycin. II. Structure
determination of tallysomycins A and B</article-title>. <source>J. Antibiot.</source>
<volume>30</volume>, <fpage>789</fpage>&#x02013;<lpage>805</lpage>.<pub-id pub-id-type="pmid">591444</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Takita</surname><given-names>T.</given-names></name>; <name><surname>Muraoka</surname><given-names>Y.</given-names></name>; <name><surname>Nakatani</surname><given-names>T.</given-names></name>; <name><surname>Fujii</surname><given-names>A.</given-names></name>; <name><surname>Umezawa</surname><given-names>Y.</given-names></name>; <name><surname>Naganawa</surname><given-names>H.</given-names></name>; <name><surname>Umezawa</surname><given-names>H.</given-names></name> (<year>1978</year>) <article-title>Chemistry
of bleomycin. XIX. Revised
structures of bleomycin and phleomycin</article-title>. <source>J. Antibiot.</source>
<volume>31</volume>, <fpage>801</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">80403</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Yun</surname><given-names>B.-S.</given-names></name>; <name><surname>George</surname><given-names>N. P.</given-names></name>; <name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name>; <name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Oh</surname><given-names>T.-J.</given-names></name>; <name><surname>Coughlin</surname><given-names>J. M.</given-names></name>; <name><surname>Zhang</surname><given-names>G.</given-names></name>; <name><surname>Tao</surname><given-names>M.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2007</year>) <article-title>Glycopeptide antitumor
antibiotic zorbamycin from <italic>Streptomyces flavoviridis</italic> ATCC 21892: Strain improvement
and structure elucidation</article-title>. <source>J. Nat. Prod.</source>
<volume>70</volume>, <fpage>402</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">17311457</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Wright</surname><given-names>G. D.</given-names></name> (<year>2011</year>) <article-title>Molecular
mechanisms of antibiotic resistance</article-title>. <source>Chem. Commun.</source>
<volume>47</volume>, <fpage>4055</fpage>&#x02013;<lpage>4061</lpage>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Reynolds</surname><given-names>P. E.</given-names></name> (<year>1989</year>) <article-title>Structure,
biochemistry, and mechanism of action of glycopeptide antibiotics</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<volume>8</volume>, <fpage>943</fpage>&#x02013;<lpage>950</lpage>.<pub-id pub-id-type="pmid">2532132</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Hayes</surname><given-names>J. D.</given-names></name>; <name><surname>Wolf</surname><given-names>C. R.</given-names></name> (<year>1990</year>) <article-title>Molecular mechanisms of drug resistance</article-title>. <source>Biochem. J.</source>
<volume>272</volume>, <fpage>281</fpage>&#x02013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">1980062</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Gatignol</surname><given-names>A.</given-names></name>; <name><surname>Durand</surname><given-names>H.</given-names></name>; <name><surname>Tiraby</surname><given-names>G.</given-names></name> (<year>1988</year>) <article-title>Bleomycin resistance conferred by
a drug-binding protein</article-title>. <source>FEBS Lett.</source>
<volume>230</volume>, <fpage>171</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="pmid">2450783</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Matsuo</surname><given-names>H.</given-names></name>; <name><surname>Mochizuki</surname><given-names>H.</given-names></name>; <name><surname>Davies</surname><given-names>J.</given-names></name>; <name><surname>Sugiyama</surname><given-names>M.</given-names></name> (<year>1997</year>) <article-title>Production of bleomycin
N-acetyltransferase in <italic>Escherichia coli</italic> and <italic>Streptomyces verticillus</italic></article-title>. <source>FEMS Microbiol.
Lett.</source>
<volume>153</volume>, <fpage>83</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">9252576</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Oda</surname><given-names>K.</given-names></name>; <name><surname>Matoba</surname><given-names>Y.</given-names></name>; <name><surname>Noda</surname><given-names>M.</given-names></name>; <name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Sugiyama</surname><given-names>M.</given-names></name> (<year>2010</year>) <article-title>Catalytic
mechanism of bleomycin N-acetyltransferase proposed on the basis of
its crystal structure</article-title>. <source>J. Biol. Chem.</source>
<volume>285</volume>, <fpage>1446</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">19889644</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Sugiyama</surname><given-names>M.</given-names></name>; <name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Shionoya</surname><given-names>M.</given-names></name>; <name><surname>Kimura</surname><given-names>E.</given-names></name>; <name><surname>Davies</surname><given-names>J. E.</given-names></name> (<year>1994</year>) <article-title>Inactivation
of bleomycin by an N-acetyltransferase in the bleomycin-producing
strain <italic>Streptomyces verticillus</italic></article-title>. <source>FEMS Microbiol. Lett.</source>
<volume>121</volume>, <fpage>81</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">7521855</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Oppenheimer</surname><given-names>N. J.</given-names></name>; <name><surname>Rodriguez</surname><given-names>L. O.</given-names></name>; <name><surname>Hecht</surname><given-names>S. M.</given-names></name> (<year>1980</year>) <article-title>Metal binding to modified bleomycins.
Zinc and ferrous complexes with an acetylated bleomycin</article-title>. <source>Biochemistry</source>
<volume>19</volume>, <fpage>4096</fpage>&#x02013;<lpage>4103</lpage>.<pub-id pub-id-type="pmid">6157406</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Brouns</surname><given-names>S. J. J.</given-names></name>; <name><surname>Wu</surname><given-names>H.</given-names></name>; <name><surname>Akerboom</surname><given-names>J.</given-names></name>; <name><surname>Turnbull</surname><given-names>A. P.</given-names></name>; <name><surname>de Vos</surname><given-names>W. M.</given-names></name>; <name><surname>van der Oost</surname><given-names>J.</given-names></name> (<year>2005</year>) <article-title>Engineering a selectable marker for hyperthermophiles</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume>, <fpage>11422</fpage>&#x02013;<lpage>11431</lpage>.<pub-id pub-id-type="pmid">15640151</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Suzuki</surname><given-names>S.</given-names></name>; <name><surname>Tada</surname><given-names>S.</given-names></name>; <name><surname>Fukuoka</surname><given-names>M.</given-names></name>; <name><surname>Taketani</surname><given-names>H.</given-names></name>; <name><surname>Tsukakoshi</surname><given-names>Y.</given-names></name>; <name><surname>Matsushita</surname><given-names>M.</given-names></name>; <name><surname>Oda</surname><given-names>K.</given-names></name>; <name><surname>Kusumoto</surname><given-names>K.-I.</given-names></name>; <name><surname>Kashiwagi</surname><given-names>Y.</given-names></name>; <name><surname>Sugiyama</surname><given-names>M.</given-names></name> (<year>2009</year>) <article-title>A novel transformation system using a bleomycin resistance
marker with chemosensitizers for <italic>Aspergillus oryzae</italic></article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<volume>383</volume>, <fpage>42</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19324021</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Sugiyama</surname><given-names>M.</given-names></name>; <name><surname>Tanaka</surname><given-names>M.</given-names></name>; <name><surname>Kumagai</surname><given-names>T.</given-names></name> (<year>1999</year>) <article-title>A mammalian
vector carrying the bleomycin
N-acetyltransferase gene from bleomycin-producing <italic>Streptomyces
verticillus</italic> as a selective marker</article-title>. <source>J. Antibiot.</source>
<volume>52</volume>, <fpage>895</fpage>&#x02013;<lpage>899</lpage>.<pub-id pub-id-type="pmid">10604759</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Sugiyama</surname><given-names>M.</given-names></name> (<year>1998</year>) <article-title>Protection of mammalian
cells from the toxicity of
bleomycin by expression of a bleomycin-binding protein gene from <italic>Streptomyces verticillus</italic></article-title>. <source>J. Biochem.</source>
<volume>124</volume>, <fpage>835</fpage>&#x02013;<lpage>841</lpage>.<pub-id pub-id-type="pmid">9756631</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Du</surname><given-names>L.</given-names></name>; <name><surname>Sanchez</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>M.</given-names></name>; <name><surname>Edwards</surname><given-names>D. J.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2000</year>) <article-title>The biosynthetic
gene cluster for the antitumor drug bleomycin from <italic>Streptomyces
verticillus</italic> ATCC15003 supporting functional interactions
between nonribosomal peptide synthetases and a polyketide synthase</article-title>. <source>Chem. Biol.</source>
<volume>7</volume>, <fpage>623</fpage>&#x02013;<lpage>642</lpage>.<pub-id pub-id-type="pmid">11048953</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Tao</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name>; <name><surname>George</surname><given-names>N. P.</given-names></name>; <name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Zhang</surname><given-names>G.</given-names></name>; <name><surname>Coughlin</surname><given-names>J. M.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2007</year>) <article-title>The tallysomycin biosynthetic
gene cluster from <italic>Streptoalloteichus hindustanus</italic> E465-94
ATCC 31158 unveiling new insights into the biosynthesis of the bleomycin
family of antitumor antibiotics</article-title>. <source>Mol. BioSyst.</source>
<volume>3</volume>, <fpage>60</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">17216057</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Galm</surname><given-names>U.</given-names></name>; <name><surname>Wendt-Pienkowski</surname><given-names>E.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>George</surname><given-names>N. P.</given-names></name>; <name><surname>Oh</surname><given-names>T.-J.</given-names></name>; <name><surname>Yi</surname><given-names>F.</given-names></name>; <name><surname>Tao</surname><given-names>M.</given-names></name>; <name><surname>Coughlin</surname><given-names>J. M.</given-names></name>; <name><surname>Shen</surname><given-names>B.</given-names></name> (<year>2009</year>) <article-title>The biosynthetic gene
cluster of zorbamycin, a member of the bleomycin family of antitumor
antibiotics, from <italic>Streptomyces flavoviridis</italic> ATCC
21892</article-title>. <source>Mol. BioSyst.</source>
<volume>5</volume>, <fpage>77</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">19081934</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Sugiyama</surname><given-names>M.</given-names></name>; <name><surname>Thompson</surname><given-names>C. J.</given-names></name>; <name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Suzuki</surname><given-names>K.</given-names></name>; <name><surname>Deblaere</surname><given-names>R.</given-names></name>; <name><surname>Villarroel</surname><given-names>R.</given-names></name>; <name><surname>Davies</surname><given-names>J.</given-names></name> (<year>1994</year>) <article-title>Characterization by molecular cloning
of two genes from <italic>Streptomyces verticillus</italic> encoding
resistance to bleomycin</article-title>. <source>Gene</source>
<volume>151</volume>, <fpage>11</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">7530224</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="book" id="cit33"><person-group person-group-type="allauthors"><name><surname>Sambrook</surname><given-names>J.</given-names></name>, and <name><surname>Russel</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>) <source>Molecular
cloning: A Laboratory Manual</source>, <edition>3</edition>rd ed., <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>, <publisher-loc>Plainview, NY</publisher-loc>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Bierman</surname><given-names>M.</given-names></name>; <name><surname>Logan</surname><given-names>R.</given-names></name>; <name><surname>O&#x02019;Brien</surname><given-names>K.</given-names></name>; <name><surname>Seno</surname><given-names>E. T.</given-names></name>; <name><surname>Rao</surname><given-names>R. N.</given-names></name>; <name><surname>Schoner</surname><given-names>B. E.</given-names></name> (<year>1992</year>) <article-title>Plasmid cloning vectors for the conjugal transfer of
DNA from <italic>Escherichia coli</italic> to <italic>Stretpomyces</italic> spp</article-title>. <source>Gene</source>
<volume>116</volume>, <fpage>43</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">1628843</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="book" id="cit35"><person-group person-group-type="allauthors"><name><surname>Kieser</surname><given-names>T.</given-names></name>, <name><surname>Bibb</surname><given-names>M.
J.</given-names></name>, <name><surname>Buttner</surname><given-names>M. J.</given-names></name>, <name><surname>Chater</surname><given-names>K. F.</given-names></name>, and <name><surname>Hopwood</surname><given-names>D. A.</given-names></name></person-group> (<year>2000</year>) <source>Practical Stretpomyces genetics</source>, <publisher-name>The John
Innes Foundation</publisher-name>, <publisher-loc>Norwich, U.K.</publisher-loc></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Meurer</surname><given-names>G.</given-names></name>; <name><surname>Hutchinson</surname><given-names>C. R.</given-names></name> (<year>1995</year>) <article-title>Functional
analysis of putative &#x003b2;-ketoacyl:acyl
carrier protein synthase and acyltransferase active site motifs in
a type II polyketide synthase of <italic>Streptomyces glaucescens</italic></article-title>. <source>J. Bacteriol.</source>
<volume>177</volume>, <fpage>477</fpage>&#x02013;<lpage>481</lpage>.<pub-id pub-id-type="pmid">7814341</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Madduri</surname><given-names>K.</given-names></name>; <name><surname>Kennedy</surname><given-names>J.</given-names></name>; <name><surname>Rivola</surname><given-names>G.</given-names></name>; <name><surname>Inventi-Solari</surname><given-names>A.</given-names></name>; <name><surname>Filippini</surname><given-names>S.</given-names></name>; <name><surname>Zanuso</surname><given-names>G.</given-names></name>; <name><surname>Colombo</surname><given-names>A. L.</given-names></name>; <name><surname>Gewain</surname><given-names>K. M.</given-names></name>; <name><surname>Occi</surname><given-names>J. L.</given-names></name>; <name><surname>MacNeil</surname><given-names>D. J.</given-names></name>; <name><surname>Hutchinson</surname><given-names>C. R.</given-names></name> (<year>1998</year>) <article-title>Production
of the antitumor drug epirubicin (4&#x02032;-epidoxorubicin) and its
precursor by a genetically engineered strain of <italic>Streptomyces
peucetius</italic></article-title>. <source>Nat. Biotechnol.</source>
<volume>16</volume>, <fpage>69</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">9447597</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Davies</surname><given-names>J.</given-names></name>; <name><surname>Wright</surname><given-names>G. D.</given-names></name> (<year>1997</year>) <article-title>Bacterial resistance
to aminoglycoside antibiotics</article-title>. <source>Trends Microbiol.</source>
<volume>5</volume>, <fpage>234</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">9211644</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Rasmussen</surname><given-names>B. A.</given-names></name>; <name><surname>Bush</surname><given-names>K.</given-names></name> (<year>1997</year>) <article-title>Carbapenem-hydrolyzing
&#x003b2;-lactamases</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>41</volume>, <fpage>223</fpage>&#x02013;<lpage>232</lpage>.<pub-id pub-id-type="pmid">9021171</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Lehmann</surname><given-names>T. E.</given-names></name>; <name><surname>Serrano</surname><given-names>M. L.</given-names></name>; <name><surname>Que</surname><given-names>L.</given-names><suffix>Jr.</suffix></name> (<year>2000</year>) <article-title>Coordination chemistry
of Co(II)-bleomycin: Its investigation through NMR and molecular dynamics</article-title>. <source>Biochemistry</source>
<volume>39</volume>, <fpage>3886</fpage>&#x02013;<lpage>3898</lpage>.<pub-id pub-id-type="pmid">10747776</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Dumas</surname><given-names>P.</given-names></name>; <name><surname>Bergdoll</surname><given-names>M.</given-names></name>; <name><surname>Cagnon</surname><given-names>C.</given-names></name>; <name><surname>Masson</surname><given-names>J. M.</given-names></name> (<year>1994</year>) <article-title>Crystal structure
and site-directed mutagenesis of a bleomycin resistance protein and
their significance for drug sequestering</article-title>. <source>EMBO
J.</source>
<volume>13</volume>, <fpage>2483</fpage>&#x02013;<lpage>2492</lpage>.<pub-id pub-id-type="pmid">7516875</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Kumagai</surname><given-names>T.</given-names></name>; <name><surname>Nakano</surname><given-names>T.</given-names></name>; <name><surname>Maruyama</surname><given-names>M.</given-names></name>; <name><surname>Mochizuki</surname><given-names>H.</given-names></name>; <name><surname>Sugiyama</surname><given-names>M.</given-names></name> (<year>1999</year>) <article-title>Characterization of the bleomycin
resistance determinant
encoded on the transposon Tn5</article-title>. <source>FEBS Lett.</source>
<volume>442</volume>, <fpage>34</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">9923599</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Sausville</surname><given-names>E. A.</given-names></name>; <name><surname>Peisach</surname><given-names>J.</given-names></name>; <name><surname>Horwitz</surname><given-names>S. B.</given-names></name> (<year>1978</year>) <article-title>Effect
of chelating agents and metal
ions on the degradation of DNA by bleomycin</article-title>. <source>Biochemistry</source>
<volume>17</volume>, <fpage>2740</fpage>&#x02013;<lpage>2746</lpage>.<pub-id pub-id-type="pmid">80226</pub-id></mixed-citation></ref></ref-list></back></article>